The goal of this activity is for learners to be better able to interpret recent data on the role of Janus kinase (JAK) inhibitors for the treatment of MF, and to apply current clinical guidelines and recommendations for incorporating these data into community-based clinical practice.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000114
- Start Date: 2024-02-14 06:00:00
- End Date: 2024-02-14 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest